The attorneys at Montgomery & Ponder, LLC are investigating claims that the cancer drug Taxotere is more likely to result in permanent hair loss (alopecia) compared to equally effective alternative chemotherapy agents.
Taxotere (docetaxel) is marketed by Sanofi-Aventis, and was initially approved by the U.S. Food & Drug Administration in 1996 to treat breast cancer. Its approved uses have since grown to include head and neck cancer, gastric cancer, prostate cancer, and non-small cell lung cancer. While Taxotere has been in wide use for more than two decades, it wasn't until December 2015 that its U.S. label was updated to note that cases of permanent alopecia had been reported among patients treated with the medication.
The lawsuits against Sanofi-Aventis allege the following:
- Knew, or should have known, about Taxotere alopecia side effects and provided proper warnings.
- Did not adequately test Taxotere to determine its risks.
- Was negligent in its design, manufacture, and marketing of Taxotere.
- Sold an unsafe, defective, and inherently dangerous drug.
- Had a duty to create a product that was not unreasonably dangerous when used as intended.
- Caused plaintiffs to suffer permanent alopecia as a result of its acts and omission.
If you or a loved one has suffered permanent hair loss following the use of Taxotere, please contact our firm immediately at (205) 377-5004.